

Claims

1 1. A method for treating neurotrauma, said method comprising
2 administering to a subject having neurotrauma a therapeutically effective amount
3 of a non-steroidal, anti-inflammatory drug (NSAID), analog, substituted form,
4 derivative, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

1 2. A method according to claim 1, wherein the NSAID is intrathecally
2 delivered.

1 3. A method according to claim 1, wherein the NSAID is
2 intraventricularly delivered.

1 4. A method according to claim 1, wherein the non-steroidal anti-
2 inflammatory drug comprises choline magnesium trisalicylate. 2189 511116

1 5. A method according to claim 1, wherein the non-steroidal anti-
2 inflammatory drug comprises sodium salicylate. 8515 5111159

1 6. A method according to claim 1, wherein the non-steroidal anti-
2 inflammatory drug comprises salicylamide. 8187 514166 5141165

863 514166
Aspirin 5141159
Salicylic acid 8190

1 7. A method according to claim 1, wherein the non-steroidal anti-
2 inflammatory drug comprises a deacetylated aspirin.

1 8. A method of treating diffuse axonal injury, said method comprising
2 administering to a subject having diffuse axonal injury a therapeutically effective
3 amount of a naturally occurring omega conotoxin, a functional fragment thereof, a
4 pharmacologically acceptable salt, ester, amide, or prodrug thereof.

1 9. A method according to claim 8, wherein the naturally occurring
2 omega conotoxin, functional fragment thereof, a pharmacologically acceptable
3 salt, ester, amide, or prodrug thereof is an N-type calcium channel blocker.

1 10. A method according to claim 8, wherein the naturally occurring
2 omega conotoxin is selected from the group consisting essentially of GVIA and
3 MVII.

1 11. A method according to claim 8, wherein said administering step
2 further comprises intrathecally delivering the omega conotoxin, functional
3 fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug
4 thereof.

1 12. A method according to claim 8, wherein said administering step
2 further comprises intraventricularly delivering the omega conotoxin, functional
3 fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug
4 thereof.

1 13. A method according to claim 8, wherein said administering step
2 further comprises delivering the omega conotoxin, functional fragment thereof, a
3 pharmacologically acceptable salt, ester, amide, or prodrug thereof to the subject
4 through an implantable pump.

1 14. A method according to claim 8, wherein said administering step
2 further comprises delivering the omega conotoxin, functional fragment thereof, a
3 pharmacologically acceptable salt, ester, amide, or prodrug thereof to the subject
4 through a spinal catheter.

1 15. A method according to claim 8, wherein the diffuse axonal injury is
2 a spastic disorder.

1 16. A method according to claim 15, wherein the spastic disorder is
2 caused by traumatic brain injury.

20250*20250*

1 17. A method according to claim 8 further including the step of
2 administering a non-steroidal anti-inflammatory drug to the subject.

1 18. A method according to claim 17, wherein the non-steroidal anti-
2 inflammatory drug comprises choline magnesium trisalicylate.

1 19. A method according to claim 17, wherein the non-steroidal anti-
2 inflammatory drug comprises sodium salicylate.

1 20. A method according to claim 17, wherein the non-steroidal anti-
2 inflammatory drug comprises salicylamide.

1 21. A method according to claim 17, wherein the non-steroidal anti-
2 inflammatory drug comprises a deacetylated aspirin.

1 22. A method for treating pain, said method comprising administering
2 to a subject having pain a therapeutically effective amount of a non-steroidal, anti-
3 inflammatory drug (NSAID), analog, substituted form, derivative, or a
4 pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

1 23. A method according to claim 22, wherein the NSAID is
2 intrathecally delivered.

1 24. A method according to claim 22, wherein the NSAID is
2 intraventricularly delivered.

1 25. A method according to claim 22, wherein the non-steroidal anti-
2 inflammatory drug comprises choline magnesium trisalicylate.

1 26. A method according to claim 22, wherein the non-steroidal anti-
2 inflammatory drug comprises sodium salicylate.

1 27. A method according to claim 22, wherein the non-steroidal anti-
2 inflammatory drug comprises salicylamide.

1 28. A method according to claim 22, wherein the non-steroidal anti-
2 inflammatory drug comprises a deacetylated aspirin.

1 29. A method for treating neuronal injury said method comprising
2 intrathecally administering to a subject having neuronal injury a therapeutically
3 effective amount of a non-steroidal, anti-inflammatory drug (NSAID), analog,
4 substituted form, derivative, or a pharmaceutically acceptable salt, ester, amide, or
5 prodrug thereof.

(112 P 2)
What is
Claim?

1 30. A method according to claim 29, wherein the NSAID is
2 intraventricularly delivered.

1 31. A method according to claim 29, wherein the non-steroidal anti-
2 inflammatory drug comprises choline magnesium trisalicylate.

1 32. A method according to claim 29, wherein the non-steroidal anti-
2 inflammatory drug comprises sodium salicylate.

1 33. A method according to claim 29, wherein the non-steroidal anti-
2 inflammatory drug comprises salicylamide.

1 34. A method according to claim 29, wherein the non-steroidal anti-
2 inflammatory drug comprises a deacetylated aspirin.

1 35. A method according to claim 29, wherein the neuronal injury is
2 caused by Lupus, inflammatory neuropathy, infection, acquired disorders,
3 transverse myelitis, Parkinson's disease, CNS vasculitis, or Alzheimer's disease.

-112R1+2